Anticipated Timeline for Game-Changing Discovery
In the shadows, a biotech stock awaits its moment. These types of companies, yet to launch a product and still in development, can be like a ticking time bomb. They burn through cash daily, trying to bring their projects to market approval, but the market finds progress hard to appreciate. As a result, the pipeline's value is most commonly undervalued. But a single positive piece of news can change everything overnight.
Take this unassuming company stationed in Planegg, a suburb of Munich. They're working on immunotherapies to combat cancer, extracting the body's defense cells and enhancing them with active compounds, all with the goal of helping the body's immune system fight tumors.
Get the lowdown on this intriguing biotech stock in the latest issue of BÖRSE ONLINE.
Other topics in this issue:
- Water, water everywhere A manufacturer of connector technology is breaking free from the automotive industry's grasp, focusing instead on water treatment. This shift gives the stock a new lease on life (p.30)
- Too modest a prognosis Fueled by massive travel demand post-pandemic, a car rental company raked in record revenues and results in the first half of the year. Yet, the stock fell. Find out who should capitalize on this dip for an entry (p.32)
- Dividend season is here A financial conglomerate has confirmed its steady business model, upping the odds for another generous payout (p.34)
- Living the good life, even in a crisis Companies like LVMH and Kering are thriving, generating record revenues. Discover which stocks are worth a second glance (p.38)
Celebrating a milestone
The inaugural issue of BÖRSE ONLINE hit the stands on 6 November 1987, priced at 4.80 DM. To commemorate its 35th anniversary, you can now revisit 4 issues at the original price - that's a savings of 50% compared to today's rates.
Choose between E-Paper, Print, or Combo subscriptions and enjoy our anniversary offers.
On a side note...
While the original article focuses on a biotech company in Planegg, it's worth noting the presence of other companies like VIVORYON THERAPeutics AG in the Munich region. VIVORYON is a clinical-stage company that engages in immuno-oncology research and has collaborated with partners such as MorphoSys and the University of Kiel to advance their portfolio [3]. They are also expanding their QPCTL technology into wider immuno-oncology applications [3]. Therefore, the promising immunotherapies for cancer treatment referenced in the article could potentially be linked to VIVORYON's research efforts.
The biotech company in Planegg, working on immunotherapies to combat cancer, is a noteworthy investment opportunity in the field of health and wellness. In the latest issue of BÖRSE ONLINE, you can read more about this intriguing biotech stock. Interestingly, another clinical-stage company, VIVORYON THERAPeutics AG, is also based in the Munich region, with a focus on immuno-oncology research that could potentially be linked to the promising immunotherapies mentioned. Additionally, finance enthusiasts might want to look into investing in companies during dividend season, such as a financial conglomerate with a history of generous payouts, as detailed in the same issue.
